Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial.

Health technology assessment (Winchester, England)·2026
Same author

Longitudinal Change in Blood-Based Biomarkers and the Association With MRI-Measured Neurodegeneration in Cognitively Unimpaired Individuals.

Neurology·2026
Same author

Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Autoimmune Encephalitis as Treatment-Responsive Cause of Rapidly Progressive Dementia: A Multicenter Prospective Cohort Study.

Neurology·2026
Same author

Plasma biomarkers for Alzheimer disease: the road from laboratory results to clinical practice.

Nature reviews. Neurology·2026
Same author

Non-MRI biomarkers should be accepted to guide treatment escalation in MS: Yes.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Related Experiment Video

Updated: Jun 30, 2026

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

8.1K

A framework for blood biomarker discovery in MS.

Emma C Tallantyre1, Sean Apap Mangion2, Charlotte E Teunissen3

  • 1Division of Psychological Medicine and Clinical Neuroscience, Cardiff University, Cardiff, UK.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|March 30, 2026
PubMed
Summary

Blood biomarkers for multiple sclerosis (MS) show promise for diagnosis and personalized treatment. Advances enable detection of low concentrations, aiding understanding of MS disease heterogeneity and guiding clinical practice.

Keywords:
Multiple sclerosisbiomarkerclinical trials

More Related Videos

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
11:03

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Published on: February 10, 2020

7.8K

Related Experiment Videos

Last Updated: Jun 30, 2026

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

8.1K
Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
11:03

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Published on: February 10, 2020

7.8K

Area of Science:

  • Biomarker discovery and development
  • Neuroimmunology
  • Translational medicine

Background:

  • Blood biomarkers offer potential for advancing multiple sclerosis (MS) understanding, diagnostics, prognostication, and personalized treatment.
  • Technological progress enables sensitive detection of biomarkers in blood, with correlations observed between blood and cerebrospinal fluid (CSF).
  • 'Omics' technologies facilitate the discovery of molecular panels reflecting MS disease heterogeneity.

Purpose of the Study:

  • To review recent discoveries and developments in blood-based biomarkers for multiple sclerosis (MS).
  • To provide a framework for understanding the current landscape and future trajectories of MS biomarker research.
  • To highlight the importance of standardization and clinical utility for biomarker adoption.

Main Methods:

  • Literature review focused on blood-based biomarkers in MS.
  • Analysis of technological advancements in biomarker detection and '-omics' approaches.
  • Discussion of key biomarkers like neurofilament light (NfL) and glial fibrillary acid protein (GFAP).

Main Results:

  • Neurofilament light (NfL) is a successful biomarker in clinical practice for MS.
  • Glial fibrillary acid protein (GFAP) shows promising development as an MS biomarker.
  • Standardization and demonstration of clinical utility are crucial for regulatory approval and adoption of new biomarkers.

Conclusions:

  • Blood-based biomarkers are pivotal for improving MS management.
  • Continued research and technological innovation are essential for realizing the full potential of MS biomarkers.
  • A standardized approach is necessary for integrating novel biomarkers into clinical practice for MS.